• Agenda
    • Programs
    • Breakout Discussions
    • Short Courses
    • Plenary Keynotes
    • Speaker Biographies
    • Training Seminars
    • Attendees
    • 1-on-1 Networking
    • Archives
  • Sponsor/Exhibitor
    • Attendee Demographics + Event Features
    • Sponsorship Opportunities
    • Current Sponsors
    • Current Exhibitors/Floorplan
    • 2020 Re-Sign Floorplan
    • Exhibit Contract
    • Exhibit Services Schedule
    • Exhibitor Prospectus
    • Lead Generation Opportunities
    • FAQs
    • Sponsor & Exhibitor Portal
  • Downloads
    • Downloads
    • Interviews
  • Travel
  • Posters
    • Poster Information
    • Poster Titles
  • Register
    • Event Registration
    • Student Registration
    • Press

Media Partners

Official Publications

  • Bio-IT World
  • Diagnostic World News

Lead Sponsoring Publications

  • The_Scientist

Sponsoring Publications

  • antibodysociety
  • Bentham-Science
  •  de-gruyter
  • DDNews-logo-S

Web Sponsors

 

  • Big3Bio
  • Bioseeker-1st-Oncology
  • BioSpace
  • Genetic-Engineering-Biotech-News
  • pharmaceutics
  • select science

 


Outlook YouTube Facebook LinkedIn Twitter
#BostonDOT19
Recap
DOT-event-highlights
Hall Pass
Final Agenda Now Available
Who Attends

2019 Programs

September 17 - 18

Target Identification and Validation
Lead Generation Strategies
Emerging Ubiquitin and Autophagy Targets
Targeting NASH
Immuno-Oncology: Emerging Targets and Therapeutics NEW
Antibodies Against Membrane Protein Targets – Part 1
Antibody Forum – Part 1
TS-icon_32x32Targeting GPCRs for Drug Discovery

September 18 - 19

RNA as a Drug Target NEW
Kinase Inhibitor Discovery
PROTACs and Targeted Protein Degradation NEW
Targeting Fibrosis NEW
GPCR-Based Drug Discovery
Antibodies Against Membrane Protein Targets – Part 2
Antibody Forum – Part 2
TS-icon_32x32Introduction to Small Molecule Drug Discovery and Development
TS-icon_32x32Practical Phenotypic Screening

Premier Sponsors

AbCellera

Ablexis Alivamab_stacked

Charles-River

Eurofins

Integral

OmniAb Ligand_Pharmaceuticals

Synthego

CHI | Cambridge HealthTech Institute

250 First Avenue, Suite 300
Needham, MA 02494

P: 781.972.5400
F: 781.972.5425
E: chi@healthtech.com

Life Science Portals

Biological Therapeutic Products

Biomarkers & Diagnostics

Biopharma Strategy

Bioprocess & Manufacturing

Chemistry

Clinical Trials &
Translational Medicine

Drug & Device Safety

Drug Discovery & Development

Drug Targets

Genomics

Healthcare

IT & Informatics

Technology & Tools For
Life Science

Therapeutic Indications

CHI Divisions

Conferences

Reports & Market Research

Barnett Educational Services

News & Advertising

Professional Services

Corporate Information

Cambridge Innovation
Institute

Executive Team

Testimonials

Mailing List

Careers

Request Information

Privacy Policy